Table of Contents

company-logo

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

GenSight Biologics Dividend Announcement

• GenSight Biologics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on GenSight Biologics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

GenSight Biologics Dividend History

GenSight Biologics Dividend Yield

GenSight Biologics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing GenSight Biologics stock? Use our calculator to estimate your expected dividend yield:

GenSight Biologics Financial Ratios

P/E ratio-1.27
PEG ratio0.08
P/B ratio-1.03
ROE72.43%
Payout ratio0.00%
Current ratio0.77
Quick ratio0.69
Cash Ratio0.41

GenSight Biologics Dividend FAQ

Does GenSight Biologics stock pay dividends?
GenSight Biologics does not currently pay dividends to its shareholders.
Has GenSight Biologics ever paid a dividend?
No, GenSight Biologics has no a history of paying dividends to its shareholders. GenSight Biologics is not known for its dividend payments.
Why doesn't GenSight Biologics pay dividends?
There are several potential reasons why GenSight Biologics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will GenSight Biologics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While GenSight Biologics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is GenSight Biologics a dividend aristocrat?
GenSight Biologics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is GenSight Biologics a dividend king?
GenSight Biologics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is GenSight Biologics a dividend stock?
No, GenSight Biologics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy GenSight Biologics stocks?
To buy GenSight Biologics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy GenSight Biologics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.